Literature DB >> 679599

Effect of human growth hormone on amobarbital metabolism in children.

G P Redmond, J J Bell, J M Perel.   

Abstract

Drug metabolism changes during the course of growth and development. Hormones mediate somatic growth and may mediate other developmental changes. To determine the effect of human growth hormone (hGH) on human drug metabolism, 6 hGH-deficient children were given single oral doses of amobarbital before and 6 wk after beginning hGH replacement therapy. Amobarbital was selected as a marker of hepatic microsomal oxidation. Half-lives rose from 13.89 +/- 2.78 hr to 22.75 +/- 3.97 hr, volume of distribution was unchanged, and clearance fell from 62.2 +/- 15.2 ml/kg/hr to 31.2 +/- 11.4 ml/kg/hr. Results indicate that hGH slows the metabolism of amobarbital, probably through an effect on the hepatic microsomal drug-oxidizing system.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 679599     DOI: 10.1002/cpt1978242213

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications.

Authors:  Jang-Ik Lee; Lei Zhang; Angela Y Men; Leslie A Kenna; Shiew-Mei Huang
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

3.  Lack of effect of growth hormone replacement therapy on CYP1A2 and xanthine oxidase activities in growth hormone-deficient children.

Authors:  Esteban Mayayo-Sinués; Ana Fanlo; Blanca Sinués; Esteban Mayayo; Jose I Labarta; Angel García de Jalón; Angel Ferrández-Longás
Journal:  Eur J Clin Pharmacol       Date:  2006-01-12       Impact factor: 2.953

4.  A database of pediatric drug effects to evaluate ontogenic mechanisms from child growth and development.

Authors:  Nicholas P Giangreco; Nicholas P Tatonetti
Journal:  Med (N Y)       Date:  2022-06-24

5.  Steady-state pharmacokinetics of phenytoin from routinely collected patient data.

Authors:  T H Grasela; L B Sheiner; B Rambeck; H E Boenigk; A Dunlop; P W Mullen; J Wadsworth; A Richens; T Ishizaki; K Chiba
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

6.  Reduced activities of cytochrome P450 1A2 and xanthine oxidase in children with growth hormone deficiency.

Authors:  M J Kennedy; D A Davis; N Smith; A Gaedigk; R E Pearce; G L Kearns
Journal:  Clin Pharmacol Ther       Date:  2008-10-08       Impact factor: 6.875

Review 7.  Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence.

Authors:  Mj Kennedy
Journal:  Clin Pharmacol Ther       Date:  2008-10-29       Impact factor: 6.875

8.  Effects of growth hormone deficiency and rhGH replacement therapy on the 6beta-hydroxycortisol/free cortisol ratio, a marker of CYP3A activity, in growth hormone-deficient children.

Authors:  Blanca Sinués; Esteban Mayayo; Ana Fanlo; Esteban Mayayo; María L Bernal; Pilar Bocos; Elena Bello; Jose I Labarta; Angel Ferrández-Longás
Journal:  Eur J Clin Pharmacol       Date:  2004-09-07       Impact factor: 2.953

9.  Pathophysiological changes that affect drug disposition in protein-energy malnourished children.

Authors:  Kazeem A Oshikoya; Idowu O Senbanjo
Journal:  Nutr Metab (Lond)       Date:  2009-12-01       Impact factor: 4.169

10.  Direct and cytokine-mediated effects of albumin-fused growth hormone, TV-1106, on CYP enzyme expression in human hepatocytes in vitro.

Authors:  Maciej Czerwiński; Immaculate Amunom; Victor Piryatinsky; Hussein Hallak; Yousif Sahly; Oren Bar-Ilan; Paul Bolliger; Merav Bassan
Journal:  Pharmacol Res Perspect       Date:  2018-04-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.